SOURCE Mylan Inc.
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
The drug maker is trying to calm public furor, but it's difficult to overcome a decade of questionable judgment.
U.S. stocks stage a rally Monday, buoyed by comments from the Federal Reserve chief Friday.
The Street's Jim Cramer joined CNBC to discuss Mylan's (MYL) announcement that it would offer a generic alternative to its EpiPens at a 50% discount.